Double blind randomized crossover trial of PF-03654764+fexofenadine in the environmental exposure unit (EEU)
Michelle L. North(Queen's University), Anne K. Ellis(Queen's University), Andrew G. Day(Kingston Health Sciences Centre), Frances Hackman(Pfizer (United Kingdom)), Terry Walker(Kingston General Hospital), Richard Allan(Pfizer (United Kingdom)), Xiaoqun Sun(Kingston General Hospital), Lisa M. Steacy(Kingston General Hospital), Barnaby Hobsbawn(Kingston General Hospital)
Cited by 3
Related Papers
Anaphylaxis—a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis
|Journal of Allergy and Clinical Immunology|2020|690
Drug allergy: A 2022 practice parameter update
|Journal of Allergy and Clinical Immunology|2022|533
Identifying critically-ill patients who will benefit most from nutritional therapy: Further validation of the “modified NUTRIC” nutritional risk assessment tool
|Clinical Nutrition|2015|526
International consensus statement on allergy and rhinology: Allergic rhinitis – 2023
|International Forum of Allergy & Rhinology|2023|475
Anaphylaxis—a practice parameter update 2015
|Annals of Allergy Asthma & Immunology|2015|473